Genetic polymorphism of CYP2C8*4 in a healthy Turkish population

Cytochrome P4502C8 (CYP2C8) is a significant member of CYP enzyme family and metabolizes about 20% of commonly prescribed drugs and endogenous compounds. Single nucleotide polymorphisms in CYP2C8 gene may change CYP2C8 enzyme activity and therefore may affect the adverse reactions and efficacy of drugs metabolized by this. The purpose of the current investigation was to detect the genotype and allele frequencies of CYP2C8*4 in a healthy Turkish population and also to compare our findings with the other populations. CYP2C8*4 polymorphism was analyzed by polymerase chain reaction-restriction fragment length method using DNA samples isolated from 109 healthy Turkish volunteers. The genotype frequencies were 95.4% for the homozygous wild-type, 4.6% for heterozygous and 0.0 % for homozygous variant. According to this, the frequencies of wild type and variant alleles were determined as 0.977 and 0.023, respectively. The genotype frequencies did not deviate from the Hardy-Weinberg equilibrium. Significant population differences were observed when the findings were compared with those of other populations. This is the first investigation to examine the frequencies of CYP2C8*4 polymorphism in Turkish population. The determination of CYP2C8*4 polymorphism may provide useful data about the pharmacokinetics, efficacy and/or toxicity of its substrates and predisposition to some diseases and may help to improve personalized therapy in the future and also contributes to epidemiological studies.

PDF

___

1. Uckun Z, Baskak B, Ozdemir H, et al. Genotype and allele frequency of CYP3A4 -392A>G in Turkish patients with major depressive disorder. Turk J Pharm Sci. 2018;15:200-6.

2. Sim SC, Ingelman-Sundberg M. The human cytochrome P450 (CYP) allele nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics. 2010;4:278-81.

3. Minhas S, Setia N, Pandita S, et al. Prevalence of CYP2C8 polymorphisms in a North Indian population. Genet Mol Res. 2013;12:2260-6.

4. Marwa KJ, Schmidt T, Sjögren M, et al. Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations. Malar J. 2014;13:420.

5. Aquilante CL, Niemi M, Gong L, et al. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet Genomics. 2013;23:721-8.

6. Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009;10:1489-510.

7. Pechandova K, Buzkova H, Matouskova O, et al. Genetic polymorphisms of CYP2C8 in the Czech Republic. Genet Test Mol Biomarkers. 2012;16:812-6.

8. Jiang H, Zhong F, Sun L, et al. Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8. Amino Acids. 2011;40:1195- 204.

9. Suarez-Kurtz G, Genro JP, de Moraes MO, et al. Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. Pharmacogenomics J. 2012;12:267-76.

10. Vicente J, González-Andrade F, Soriano A, et al. Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study. Mol Biol Rep. 2014;41:1267-72.

11. Korytina G, Kochetova O, Akhmadishina L, et al. Polymorphisms of cytochrome p450 genes in three ethnic groups from Russia. Balkan Med J. 2012;29(3):252-60.

12. 1000 Genomes Project. http://phase3browser.1000genomes.org/ access date 28.11.2019

13. Bahadur N, Learth JBS, Mutch E, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochem Pharmacol. 2002;64:1579-89.

14. Weise A, Grundler S, Zaumsegel D, et al. Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping. Clin Lab. 2004;50:141-8.

15. Jernström H, Bågeman E, Rose C, et al. CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients. Br J Cancer. 2009;101:1817-23.

16. Jaja C, Bowman L, Wells L, et al. Preemptive genotyping of CYP2C8 and CYP2C9 allelic variants involved in NSAIDs metabolism for sickle cell disease pain management. Clin Transl Sci. 2015;8:272-80.

17. Cavaco I, Strömberg-Nörklit J, Kaneko A, et al. CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. Eur J Clin Pharmacol. 2005;61:15-8.

18. Kudzi W, Dodoo AN, Mills JJ. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet. 2009;10:124.

19. Muthiah YD, Lee WL, Teh LK, et al. Genetic polymorphism of CYP2C8 in three Malaysian ethnics: CYP2C8*2 and CYP2C8*3 are found in Malaysi Indians. J Clin Pharm Ther. 2005;30:487-90.

20. Nakajima M, Fujiki Y, Noda K, et al. Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab Dispos. 2003;31:687-90.

21. Dorado P, Cavaco I, Cáceres MC, et al. Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. Eur J Clin Pharmacol. 2008;64: 967-70.

22. Barratt DT, Cox HK, Menelaou A, et al. CYP2C8 genotype significantly alters Imatinib metabolism in chronic myeloid leukaemia patients. Clin Pharmacokinet. 2017;56:977-85.

23. Daly AK, Aithal GP, Leathart JB, et al. Genetics susceptibility to diclofenacinduced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology. 2007;132:272-81.

24. Lazarska KE, Dekker SJ, Vermeulen NPE, et al. Effect of UGT2B7*2 and CYP2C8*4 polymorphisms on diclofenac metabolism. Toxicol Lett. 2018;284:70-8.

25. Bergmann TK, Brasch-Andersen C, Gréen H, et al. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J. 2011;11:113- 20.

26. Henningsson A, Marsh S, Loos WJ, et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res. 2005;11:8097-104.

27. Marsh S, Somlo G, Li X, et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 2007;7:362-5.

28. Niemi M, Leathart JB, Neuvonen M, et al. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther. 2003;74:380-7.